UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 135

Sortiert nach

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Leukemia, 2021-01, Vol.35 (1), p.1-17

2021

Volltextzugriff (PDF)

Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies

American journal of hematology, 2023-05, Vol.98 (5), p.794-800

2023

Volltextzugriff (PDF)

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

American journal of hematology, 2020-06, Vol.95 (6), p.594-603

2020

Volltextzugriff (PDF)

Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives

Cancer, 2024-06, Vol.130 (12), p.2091-2097

2024

Volltextzugriff (PDF)

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.787-798

2012

Volltextzugriff (PDF)

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

The New England journal of medicine, 2021-03, Vol.384 (11), p.1028-1037

2021

Volltextzugriff (PDF)

Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature

British journal of haematology, 2024-07, Vol.205 (1), p.48-60

2024

Volltextzugriff (PDF)

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts

British journal of haematology, 2022-07, Vol.198 (2), p.317-327

2022

Volltextzugriff (PDF)

Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies

Cancer, 2023-06, Vol.129 (11), p.1681-1690

2023

Volltextzugriff (PDF)

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Leukemia, 2022-05, Vol.36 (5), p.1408-1411

2022

Volltextzugriff (PDF)

Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia

The New England journal of medicine, 2014-07, Vol.371 (2), p.188-189

2014

Volltextzugriff (PDF)

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

Journal of clinical oncology, 2011-10, Vol.29 (29), p.3907-3913

2011

Volltextzugriff (PDF)

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2881-2892

2021

Volltextzugriff (PDF)

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Journal of clinical oncology, 2011-02, Vol.29 (6), p.761-770

2011

Volltextzugriff (PDF)

Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement

British journal of haematology, 2022-02, Vol.196 (3), p.676-680

2022

Volltextzugriff (PDF)

Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC‐PM

American journal of hematology, 2024-04, Vol.99 (4), p.741-744

2024

Volltextzugriff (PDF)

Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study

American journal of hematology, 2021-01, Vol.96 (1), p.80-88

2021

Volltextzugriff (PDF)

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups

Bone marrow transplantation (Basingstoke), 2021-08, Vol.56 (8), p.1888-1899

2021

Volltextzugriff (PDF)

An inherited gain‐of‐function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms

British journal of haematology, 2022-07, Vol.198 (1), p.131-136

2022

Volltextzugriff (PDF)

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

The New England journal of medicine, 2021-03, Vol.384 (11), p.1028-1037

2021

Volltextzugriff (PDF)

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia

American journal of hematology, 2017-10, Vol.92 (10), p.1062-1067

2017

Volltextzugriff (PDF)

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

The New England journal of medicine, 2015-01, Vol.372 (5), p.426-435

2015

Volltextzugriff (PDF)

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

British journal of haematology, 2018-07, Vol.182 (2), p.279-284

2018

Volltextzugriff (PDF)

1 – 25 von 135

Suche als RSS-Feed

Aktive Filter

KollektionEZB Free E-Journals

KollektionJournals@Ovid

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(133)
Mit Volltextzugriff
(133)

Publikationsform

Sprache

Englisch
(135)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(67)
Science & Technology
(67)
Humans
(57)
Hematology
(46)
Female
(30)
Male
(29)
Oncology
(29)
Middle Aged
(26)
Myelofibrosis
(26)
Aged
(21)
Adult
(20)
Mutation
(19)
Patients
(18)
Tumors
(17)
Life Sciences
(16)
Janus Kinase 2
(14)
Primary Myelofibrosis - Drug Therapy
(13)
Treatment Outcome
(13)
Biological And Medical Sciences
(12)
Hematologic And Hematopoietic Diseases
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

Myeloproliferative neoplasms and splanchnic vein thrombosis: Contemporary diagnostic and therapeutic strategies

Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

Myelofibrosis: Current unmet needs, emerging treatments, and future perspectives

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature

Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts

Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT‐I and COMFORT‐II studies

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

Interferon Alfa Therapy in CALR-Mutated Essential Thrombocythemia

Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Revisiting Diagnostic performances of serum erythropoïetin level and JAK2 mutation for polycythemias: analysis of a cohort of 1090 patients with red cell mass measurement

Comparative clinical and molecular landscape of primary and secondary myelofibrosis: Superior performance of MIPSS70+ v2.0 over MYSEC‐PM

Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study

Ruxolitinib before allogeneic hematopoietic transplantation in patients with myelofibrosis on behalf SFGM-TC and FIM groups

An inherited gain‐of‐function risk allele in EPOR predisposes to familial JAK2V617F myeloproliferative neoplasms

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia

Long-term follow-up of JAK2 exon 12 polycythemia vera: a French Intergroup of Myeloproliferative Neoplasms (FIM) study

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera

Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide

Aktive Filter

Suchergebnisse filtern